^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IMPDH inhibitor

    Related drugs:
    1m
    Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma. (PubMed, Front Immunol)
    She was successfully treated with high-dose glucocorticoids, mycophenolate mofetil, and intravenous immunoglobulin with resolution of presenting symptoms...Additionally, we identified a differentiated CD27- CD28- effector memory (EM) CD4+ subset that was associated with clinical disease activity and contracted with glucocorticoid use administration. This illustrates a unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide insight into the underlying pathophysiology of irAEs, and to guide and gauge response to immunomodulatory therapy, thus facilitating a precision medicine approach within the diagnostic and treatment framework for irAEs.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
    1m
    SPI-1005 Treatment in Severe COVID-19 Patients (clinicaltrials.gov)
    P2, N=25, Completed, Sound Pharmaceuticals, Incorporated | Enrolling by invitation --> Completed | N=60 --> 25
    Trial completion • Enrollment change
    1m
    Study to Evaluate SPI-1005 in Adults With Meniere's Disease (clinicaltrials.gov)
    P1/2, N=40, Completed, Sound Pharmaceuticals, Incorporated | Phase classification: P1b --> P1/2
    Phase classification
    2ms
    MT2015-29: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (clinicaltrials.gov)
    P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    2ms
    Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Fox Chase Cancer Center
    New P2 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    prednisone
    2ms
    PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=82, Completed, Duke University | N=167 --> 82
    Enrollment change • HEOR
    2ms
    Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov)
    P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed
    Trial completion
    |
    everolimus • cyclosporin A microemulsion
    2ms
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    2ms
    Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy (clinicaltrials.gov)
    P1, N=24, Enrolling by invitation, Stanford University | Trial completion date: May 2028 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2030 | Not yet recruiting --> Enrolling by invitation
    Enrollment open • Trial completion date • Trial primary completion date
    2ms
    Immunopathogenesis of Mayaro Virus-Induced Chronic Arthritis: From Inflammatory Pathways to Targeted Therapeutic Strategies. (PubMed, Vector Borne Zoonotic Dis)
    The article provides a critical evaluation of current and developing therapeutic strategies, including antiviral agents such as favipiravir and immunomodulatory agents targeting IL-1β, tumor necrosis factor, and IL-6 signaling. Understanding the interplay between viral determinants and host immune responses is critical for the rational design of effective interventions against MAYV-induced chronic inflammation and arthritis.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    2ms
    MYCOHYPE: An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis (clinicaltrials.gov)
    P4, N=144, Active, not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    prednisolone
    2ms
    A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sound Pharmaceuticals, Incorporated | Phase classification: P2b --> P2 | N=180 --> 0 | Trial completion date: Oct 2021 --> Jun 2026 | Unknown status --> Withdrawn | Trial primary completion date: Jun 2021 --> Jun 2026
    Phase classification • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date